Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-07-2020 | Edema | Retinal Disorders

Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion

Authors: Yeo-Yang Koh, Chi-Chun Lai, Wei-Chi Wu, Yih-Shiou Hwang, Kuan-Jen Chen, Nan-Kai Wang, Tun-Lu Chen, Jerry Chien-Chieh Huang, Laura Liu, Ling Yeung

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2020

Abstract

Purpose

To evaluate prognostic factors in young patients with central retinal vein occlusion (CRVO).

Methods

Retrospective case series. CRVO patients aged ≤ 50 and follow-up ≥ 6 months were enrolled. The best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline, 3 months, 6 months, and last visit were documented. Severity of retinopathy was graded by comparing to standard photos. Prognostic factors associated with visual outcome at 6 months were evaluated by multiple linear regression models.

Results

A total of 73 eyes from 69 patients with mean age 37.6 ± 8.5 were enrolled. Forty-seven (68%) patients were male. The mean follow-up duration was 25.9 ± 23.0 months. LogMAR BCVA improved from 0.979 ± 0.785 at baseline to 0.594 ± 0.748 at the 6 months (p < 0.001) and CRT improved from 475 ± 222 μm to 299 ± 104 μm (p < 0.001). Forty-eight (66%) eyes required anti-vascular endothelial growth factor (anti-VEGF) treatment. The mean number of injections was 2.25 ± 1.41 in the first 6 months and 75% of eyes received ≦ 3 injections during the clinical course. The baseline BCVA (coefficient 0.518, p < 0.001), grade of retinal hemorrhage (coefficient 0.230, p = 0.006), grade of retinal venous engorgement (coefficient 0.238, p = 0.011), grade of optic disc edema (coefficient − 0.226, p = 0.005), and diabetes mellitus (coefficient 0.264, p = 0.047) were the independent factors associated with visual outcome at 6 months.

Conclusions

Baseline clinical features are useful for the prediction of visual outcome at 6 months in young CRVO patients.

Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al (2010) International eye disease C: the prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319CrossRef

Kohner EM, Cappin JM (1974) Do medical conditions have an influence on central retinal vein occlusions? Proc R Soc Med 67:1052–1054PubMedPubMedCentral

Walters RF, Spalton DJ (1990) Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Ophthalmol 74:30–35CrossRef

Hayreh SS, Podhajsky PA, Zimmerman MB (2011) Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 118:119–133CrossRef

Lindsell LB, Lai MM, Fine HF (2015) Current concepts in managing retinal vein occlusion in young patients. Ophthalmic Surg Lasers Imaging Retina 46:695–701CrossRef

Rothman AL, Thomas AS, Khan K, Fekrat S (2019) Central retinal vein occlusion in young individuals: a comparison of risk factors and clinical outcomes. Retina 39:1917–1924CrossRef

Kuo JZ, Lai CC, Ong FS, Shih CP, Yeung L, Chen TL et al (2010) Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality. Retina 30:479–484CrossRef

Recchia FM, Carvalho-Recchia CA, Hassan TS (2004) Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol 122:317–321CrossRef

Wittstrom E (2017) Central retinal vein occlusion in younger Swedish adults: case reports and review of the literature open. Ophthalmol J 11:89–102

10.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133CrossRef

11.

Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G et al (2013) VEGF trap-eye for macular edema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97:278–284CrossRef

12.

Bressler SB, Edwards AR, Andreoli CM, Edwards PA, Glassman AR, Jaffe GJ et al (2015) Reproducibility of Optovue RTVue optical coherence tomography retinal thickness measurements and conversion to equivalent Zeiss stratus metrics in diabetic macular edema. Transl Vis Sci Technol 4:5CrossRef

13.

Hayreh SS, Zimmerman MB (2015) Fundus changes in central retinal vein occlusion. Retina 35:29–42CrossRef

14.

Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121:202–208CrossRef

15.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRef

16.

Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG (2013) Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 120:795–802CrossRef

17.

The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491CrossRef

18.

Muraoka Y, Uji A, Tsujikawa A, Murakami T, Ooto S, Suzuma K et al (2017) Association between retinal hemorrhagic patterns and perfusion status in eyes with acute central retinal vein occlusion. Retina 37:500–508CrossRef

19.

Yasuda S, Kachi S, Kondo M, Ueno S, Kaneko H, Terasaki H (2015) Significant correlation between retinal venous tortuosity and aqueous vascular endothelial growth factor concentration in eyes with central retinal vein occlusion. PLoS One 10:e0134267CrossRef

20.

Hayreh SS (1972) Optic disc vasculitis. Br J Ophthalmol 56:652–670CrossRef

21.

Lonn LI, Hoyt WF (1966) Papillophlebitis: a cause of protracted yet benign optic disc edema. Eye Ear Nose Throat Mon 45:62PubMed

22.

Fong AC, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L et al (1992) Central retinal vein occlusion in young adults (papillophlebitis). Retina 12:3–11CrossRef

23.

Beaumont PE, Kang HK (2000) Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol 118:1357–1363CrossRef

24.

Hayreh SS, van Heuven WA, Hayreh MS (1978) Experimental retinal vascular occlusion. I Pathogenesis of central retinal vein occlusion. Arch Ophthalmol 96:311–323CrossRef

25.

Hayreh SS (1965) Occlusion of the central retinal vessels. Br J Ophthalmol 49:626–645CrossRef

26.

Santiago JG, Walia S, Sun JK, Cavallerano JD, Haddad ZA, Aiello LP et al (2014) Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion. Eye (London, England) 28:259–268CrossRef

27.

Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y (2017) Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol 11:441–447CrossRef

28.

Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO (2010) Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost 103:299–305CrossRef

29.

Bremond-Gignac D, Daruich A, Gallet M, Menoud PA, Nowomiejska K, Rejdak R et al (2019) Central retinal vein occlusion in otherwise healthy children and adolescents: association with multigenetic variants of thrombophilia. Retina. https://doi.org/10.1097/IAE.0000000000002563

30.

Kuhli-Hattenbach C, Hellstern P, Nägler DK, Kohnen T, Hattenbach LO (2017) Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. Ophthalmic Genet 38:413–417CrossRef

31.

Liu Q, Lahey JM, Karlen R, Stewart JM (2018) Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Retina 38:1175–1179CrossRef

32.

Larsen M, Waldstein SM, Boscia F, Gerding H, Mones J, Tadayoni R et al (2016) Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123:1101–1111CrossRef

33.

Blanc J, Deschasse C, Kodjikian L, Dot C, Bron AM, Creuzot-Garcher C (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol 256:1441–1448CrossRef

34.

Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R et al (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253:2095–2102CrossRef

35.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S (2011) Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 31:838–845CrossRef

36.

Ozkok A, Saleh OA, Sigford DK, Heroman JW, Schaal S (2015) THE OMAR STUDY: comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina 35:1393–1400CrossRef

37.

Evans K, Wishart PK, McGalliard JN (1993) Neovascular complications after central retinal vein occlusion. Eye (London, England) 7(Pt 4):520–524CrossRef

38.

Rong AJ, Swaminathan SS, Vanner EA, Parrish RK 2nd (2019) Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol 204:62–69CrossRef

39.

Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL et al (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina 34:1728–1735CrossRef

40.

Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ et al (2011) SCORE study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology 118:1364–1372CrossRef

41.

Ryu CL, Elfersy A, Desai U, Hessburg T, Edwards P, Gao H (2014) The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol 2014:317694CrossRef

Title: Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion
Authors: Yeo-Yang Koh
Chi-Chun Lai
Wei-Chi Wu
Yih-Shiou Hwang
Kuan-Jen Chen
Nan-Kai Wang
Tun-Lu Chen
Jerry Chien-Chieh Huang
Laura Liu
Ling Yeung
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keyword: Edema
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-04679-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2020

Three-dimensional characterisation of the globe position in the orbit

Reproducibility and agreement of four anterior segment-optical coherence tomography devices for anterior chamber angle measurements

Feelings, preoperative anxiety, and need for information in patients undergoing intravitreal injections

Demographic, clinical features, and outcomes of pediatric non-penetrating ocular foreign bodies

New retinal tack designs: an analysis of retention forces in human scleral tissue

Optic neuritis in German children: clinical findings and association with multiple sclerosis